RaySearch has announced that RayStation 9 has been granted regulatory clearance in China. The approval will bring notable additional features to cancer centers in the country, including Plan Explorer, Monte Carlo dose calculation for proton therapy, support for planning of Accuray Radixact and TomoTherapy treatment delivery systems, as well as a wide range of system-wide improvements. This regulatory clearance is major step forward for RaySearch in terms of its offering to customers in China.
RayStation, a treatment planning system, combines the user experience with advanced functionality, support for a broad range of machines, leading automation features and very high calculation speeds.
RaySearch has local presence with its own subsidiary in China since 2017 and registers a growing demand for RayStation from Chinese customers. Currently, there are around 60 customers for RayStation in the country.
Johan Löf, founder and CEO, RaySearch, says: “The unique features of RayStation 9 will now be available to centers across China. The Chinese market offers significant growth opportunities for RaySearch and by this regulatory clearance we can meet the needs of more centers in the country.”Back To Top
RayStation 9 Receives Regulatory Clearance in China. Appl Rad Oncol.